1. Home
  2. ENTX vs CATO Comparison

ENTX vs CATO Comparison

Compare ENTX & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.16

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Logo Cato Corporation (The)

CATO

Cato Corporation (The)

HOLD

Current Price

$2.99

Market Cap

58.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
CATO
Founded
2010
1946
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
62.6M
58.0M
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
ENTX
CATO
Price
$1.16
$2.99
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
175.6K
74.9K
Earning Date
05-08-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
68.04
EPS
0.25
N/A
Revenue
$42,000.00
$653,812,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.72
N/A
Revenue Growth
N/A
0.62
52 Week Low
$0.91
$2.20
52 Week High
$3.22
$4.92

Technical Indicators

Market Signals
Indicator
ENTX
CATO
Relative Strength Index (RSI) 48.33 50.78
Support Level $1.17 $2.79
Resistance Level $1.61 $3.28
Average True Range (ATR) 0.13 0.18
MACD 0.01 0.02
Stochastic Oscillator 56.25 46.75

Price Performance

Historical Comparison
ENTX
CATO

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About CATO Cato Corporation (The)

The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.

Share on Social Networks: